Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections
and hospitalization in infants under 1 year of age and there is currently no market-approved …

Sensitization of the humoral immune response to invading viruses and production of
antiviral antibodies forms part of the host antiviral repertoire. Paradoxically, for a number of …

Understanding immune responses to viral infections is crucial to progress in the quest for
effective infection prevention and control. The host immunity involves various mechanisms to …

Neutralizing polyclonal antibody to respiratory syncytial virus (RSV) has been shown to be
an effective prophylactic agent when administered intravenously in high-risk infants. This …

Besides the common receptor/coreceptor‐dependent mechanism of cellular attachment,
some viruses rely on antiviral antibodies for their efficient entry into target cells. This …

Antiviral antibodies constitute an important component of the host immune response against
viral infections and serve to neutralize and reduce infectivity of the virus. However, these …

A stabilized form of the respiratory syncytial virus (RSV) fusion (F) protein has been explored
as a vaccine to prevent viral infection because it presents several potent neutralizing …

Respiratory synctial virus (RSV) infections are a common and concerning conundrum. This
ubiquitous agent is the major respiratory pathogen of young children, with life‐threatening …

Antibody-dependent enhancement (ADE) has been associated with severe disease
outcomes in several viral infections, including respiratory infections. In vitro and in vivo …

The dogma is that the human immune system protects us against pathogens. Yet, several
viruses, like dengue virus, antagonize the hosts' antibodies to enhance their viral load and …